Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial

Autor: Mark Midei, Alex I. Malinin, Victor L. Serebruany, David R. Lowry, H. Meilman

Publikováno v: International Journal of Clinical Practice. 60:863-866

Summary Therapy with aspirin and/or adenosine diphosphate (ADP) receptor blockers is associated with better outcomes via inhibition of platelet activity, and subsequent reduction of ischemic vascular events. Non-compliance (NC) is a well-recognised h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::021640ca9ea4cba7aa797d68559575b6
https://doi.org/10.1111/j.1742-1241.2006.00999.x

Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: A randomized, single-blind, 30-day trial

Autor: Daniel F. Hanley, Alex N. Pokov, Alex I. Malinin, Victor L. Serebruany

Publikováno v: Clinical Therapeutics. 30:249-259

Clopidogrel, aspirin (ASA), and the fixed-dose combination of extended-release dipyridamole and ASA (ER-DP+ASA) are widely used in post-stroke regimens.This study compared serial changes in multiple biomarkers of platelet activation with ER-DP+ASA an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c45310743ee0cbbb6c1e4e3cf00fe7
https://doi.org/10.1016/j.clinthera.2008.02.006

Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study

Autor: Dan Atar, Victor L. Serebruany, François Lespérance, Alex I. Malinin, Nancy Frasure-Smith, Louis T. van Zyl, Alex N. Pokov

Publikováno v: Neuropsychopharmacology. 32:2369-2374

There is an increasing body of evidence suggesting that selective serotonin reuptake inhibitors exhibit clinical benefit beyond treating depression, by simultaneously inhibiting platelet activity. We recently demonstrated that escitalopram (ESC), but

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b33a27bf88d83ba77c8ecbfc3d448657
https://doi.org/10.1038/sj.npp.1301355

Valves in the Heart of the Big Apple V: Evaluation and Management of Valvular Heart Diseases 2007.Third Annual Scientific Session: Heart Valve Society of America, New York City, N.Y., April 12–14, 2007

Autor: Kurt Boman, Harun Evrengul, E. Vizzardi, Jacob Goldstein, M. Metra, Daniel P. Shmorhun, Yu Shu Li, Chia-Ti Tsai, Pei-Leun Kang, Ke Ping Yang, Kai Mortensen, Gerhard Blazek, Claudia Stöllberger, Christopher Gans, Rodolfo Ventura, Debabrata Mukherjee, J. Kogias, Holger Diedrichs, Sena Tokay, Sungha Park, Seyhan Tanriverdi, James Blasetto, Adam Torbicki, David Köhler, Ken-ichi Sugimoto, Joško Osredkar, C. Fiorina, Akira Suda, Pablo Ancillo, Ahmet Oktay, Se-Jung Yoon, D. Tanne, Gertrud Wüstefeld, Refik Erdim, Matthias Pfisterer, Teiichi Yamane, Anthony Roselli, Daniel Petrovič, Chi Young Shim, Erol Saygili, Xue-Bing Li, H. Asuman Kaftan, Muhammet Ali Aydin, Uwe Nixdorff, Barbara Lewis, Susan Harris, Zaza Iakobishvili, Dariusz A. Kosior, Ulrich Keller, Renata Verhovec, Basil S. Lewis, Lutz Klinghammer, V. Boyko, V. Caldir, Ronen Jaffe, Basheer Karkabi, Daniel Seidensticker, Robert H. G. Schwinger, Shih Kai Lin, Tsutomu Yoshikawa, S. Behar, John Kao, Midori Yamakawa, Andreas Schuchert, Yung-Zu Tseng, Mona Olofsson, Ronen Rubinshtein, Miodrag Filipovic, Kimiaki Komukai, U. Guray, Yuichiro Maekawa, Gabriele Pfitzer, Ling-Ping Lai, Zenon S. Kyriakides, Hiroyuki Hazeyama, Ralph Stephan von Bardeleben, Manfred D. Seeberger, Konrad Frank, Josef Finsterer, Kamran Aghasadeghi, S. Kormaz, Chanmi Park, Hartwig Wolburg, Hemender S. Vats, Elinor Miller, M. Haim, Yohei Ohno, Param P. Sharma, Takashi Kohno, U. Goldbourt, Hiromichi Hara, Hyun Young Park, Joji Urata, Taro Date, Ming-Ren Chen, S. Nodari, Shye-Jao Wu, Nurullah Tuzun, Shiro Iwanaga, A. Serdar Fak, Donald G. Vidt, S. Cay, Chun-Peng Liu, Doron Zahger, Holger K. Eltzschig, Mojca Globočnik Petrovič, Ing-Sh Chiu, Namsik Chung, Yasar Enli, Juey-Jen Hwang, S. Sideris, David J. Moliterno, Jonathan Rosen, Toshihisa Anzai, H. Sasmaz, Esra Saygili, Yuan-Sheng Liu, Halil Tanriverdi, K. Tsatiris, David Hasdai, Toshihide Shinozaki, M.B. Yilmaz, Mei-Hwan Wu, R. Zimlichman, Borut Peterlin, Gautam Nayak, M. Bonios, Fu-Tien Chiang, Moshe Y. Flugelman, L. Dei Cas, Knut Gjesdal, Maria Winkler-Dworak, Susanne Mohr-Kahaly, Carsten Zobel, Amir Aslani, Grzegorz Opolski, Tobias Eckle, Guang Yuan Mar, Omur Kuru, Y. Guray, Dan Edebro, Fernando Arós, Pedro Morillas, David A. Halon, Rita Dictiar, Tao Yu Lee, Deniz Seleci, Takashi Sakamoto, Raban Jeger, Stephanie Zug, Jochen Müller-Ehmsen, Ping Zhang, Hai-Cheng Zhang, Bermseok Oh, Hidehiro Kaneko, Zhi-Hong Zhao, Shmuel Gottlieb, Chuen-Wang Chiou, Thomas Meinertz, Z. Matas, Hung-Chi Lue, Jiunn-Lee Lin, Dan Atar, Yangsoo Jang, José Luis Priego Bermejo, Gökmen Gemici, Karin Klingel, Alex I. Malinin, George Arealis, Hakan Tezcan, Savvas Nikolidakis, Young Guk Ko, Daisuke Utsunomiya, Donghoon Choi, Birgit Bölck, Satoshi Ogawa, Kotaro Naito, Arne Warth, Solomon Behar, Pedro Pabón, John J. Hayes, Yuan Xu, M. Benderly, Humberto Vidaillet, Ming Hua Luo, Hui-Chong Li, Avital Porter, Yasushi Asakura, C. Melexopoulou, Stephan Willems, Jou-Kou Wang, Yasuo Sugano, Taiji Nishiharu, Marion Faigle, P. Exarchos, Seibu Mochizuki, Haim Hammerman, Yasuyuki Yamashita, Robert J. Goldberg, Shih Hung Hsiao, Hung Tae Kim, Nevzat Karabulut, Carmen Fernández, Hanoch Hod, Michael Koutouzis, Vicente Bertomeu, Obaida R. Rana, Hannes Reuter, Kazuo Awai, James Shepherd, Ikuo Taniguchi, Victor L. Serebruany, Chuen-Den Tseng, Ji-Hong Guo

Publikováno v: Cardiology. 107:444-456

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37bd529a1ccfcbab8f864ba4494d17fa
https://doi.org/10.1159/000101431

Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial?

Autor: Dan Atar, Victor L. Serebruany, Dominick J. Angiolillo, Alex I. Malinin, Umesh Arora, Alex N. Pokov

Publikováno v: Thrombosis Research. 119:175-181

Introduction Ongoing search for the optimal dosing regimens, and valid concerns that some GPIIb/IIIa inhibitors may cause rebound platelet activation are limiting the use of these agents in patients with acute vascular events. Materials and methods W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb37bbdbbb9e852e717c95655801005
https://doi.org/10.1016/j.thromres.2006.02.004